This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies

LAST CHANCE: REGISTER BY MAY 20 TO SAVE UP TO $300

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
June 14-16, 2022
Delivered as a Hybrid EventIntercontinental Mark Hopkins Hotel, San Francisco, California

Arthur Stril
Chief Business Officer at Cellectis, USA

Profile

Arthur Stril serves as Cellectis’ Chief Business Officer since September 2020, overseeing business development, strategy, and program management. Arthur joined Cellectis in July 2018 as Vice President, Corporate Development. Arthur began his career at the European Commission’s Directorate-General for Competition, controlling global pharmaceutical mergers such as the Novartis/GSK and Sanofi/Boehringer Ingelheim asset swaps, Pfizer’s acquisition of Hospira, and Teva’s acquisition of Actavis Generics. He later became Head of the Hospital Financing unit at the French Ministry of Health, where he led a team responsible for the €80bn hospital budget. Arthur graduated from the École Normale Supérieure, Paris & Cambridge University, and holds a diploma in Immunotherapy from the Université Paris-Descartes. Arthur is also a member of the French Corps des Mines.

Agenda Sessions

  • Panel: Gene Editing Tools to Produce Smart CART Cells

    11:30am